Get on Wall Street from StreetInsider Premium… Get a 1 week free trial here.
Johnson & Johnson (NYSE: JNJ) announced:
We are pleased to confirm that the US Food and Drug Administration (FDA) has authorized an extension of the shelf life of Johnson & Johnson’s single-dose COVID-19 vaccine from 3 months to 4.5 months. The decision is based on data from ongoing stability studies that have shown that the vaccine is stable for 4.5 months when refrigerated at 36–46 degrees Fahrenheit (2–8 degrees Celsius). Vaccine providers should visit www.vaxcheck.jnj to confirm the latest expiration dates for our vaccine, including those currently available for administration throughout the United States.
The disposable vaccine, which protects and prevents hospitalization and death, is an essential tool in the global fight against COVID-19. Data from our Phase 3 ENSEMBLE study demonstrates the efficacy of our single-dose vaccine against COVID-19, including against viral variants that are widespread. These results remain the same regardless of race and ethnicity, age, geographic location, and comorbid conditions.
We continue to work with the US government and health authorities to support the use of our vaccine, which plays an important role in the fight against the pandemic, including among those looking to get a full shot in one shot.